Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF

Gene Therapy

Volumn 19, Issue 7, 2012, Pages 711-723

  Choi, K J ^a   Zhang, S N ^a,b   Choi, I K ^c   Kim, J S ^a   Yun, C O ^d  

^a Yonsei University College of Medicine   (South Korea)

^b YANBIAN UNIVERSITY   (China)

^c Yonsei University   (South Korea)

^d Hanyang University   (South Korea)

Author keywords

GM CSF; IL 12; oncolytic adenovirus

Indexed keywords

CD86 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; ONCOLYTIC ADENOVIRUS; VASCULOTROPIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; T LYMPHOCYTE; TH1 CELL; THYMUS ATROPHY;

ADENOVIRIDAE; ANIMALS; ANTIGEN-PRESENTING CELLS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; GENETIC THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOLOGIC MEMORY; INTERLEUKIN-12; KILLER CELLS, NATURAL; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; ONCOLYTIC VIRUSES; T-LYMPHOCYTES, CYTOTOXIC; THYMUS GLAND;

ADENOVIRIDAE; MURINAE;

EID: 84863724269     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.125     Document Type: Article

References (42)

1. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-296. (Pubitemid 46697910)
2. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004; 305: 200-205. (Pubitemid 38886725)
3. Podhajcer OL, Lopez MV, Mazzolini G. Cytokine gene transfer for cancer therapy. Cytokine Growth Factor Rev 2007; 18: 183-194. (Pubitemid 46401434)
4. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4: 11-22. (Pubitemid 38111131)
5. Chada S, Ramesh R, Mhashilkar AM. Cytokine-and chemokine-based gene therapy for cancer. Curr Opin Mol Ther 2003; 5: 463-474. (Pubitemid 37304711)
6. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007; 13: 4677-4685. (Pubitemid 47294773)
7. Kanegane C, Sgadari C, Kanegane H, Teruya-Feldstein J, Yao L, Gupta G et al. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol 1998; 64: 384-392. (Pubitemid 28409246)
8. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543. (Pubitemid 23111402)
9. Osaki T, Peron JM, Cai Q, Okamura H, Robbins PD, Kurimoto M et al. IFN-gammainducing factor/IL-18 administration mediates IFN-gamma-and IL-12-independent antitumor effects. J Immunol 1998; 160: 1742-1749. (Pubitemid 28106460)
10. Marshall E. Sciencescope. Science 1995; 268: 1555.
11. Yoshida T, Ohnami S, Aoki K. Development of gene therapy to target pancreatic cancer. Cancer Sci 2004; 95: 283-289. (Pubitemid 38519466)
12. Lee YS, Kim JH, Choi KJ, Choi IK, Kim H, Cho S et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res 2006; 12: 5859-5868. (Pubitemid 44629619)
13. Choi KJ, Kim JH, Lee YS, Kim J, Suh BS, Kim H et al. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Therapy 2006; 13: 1010-1020. (Pubitemid 43905854)
14. Huang JH, Zhang SN, Choi KJ, Choi IK, Kim JH, Lee M et al. Therapeutic and tumorspecific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol Ther 2010; 18: 264-274.
15. Hwang KS, Cho WK, Yoo J, Seong YR, Kim BK, Kim S et al. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity. Cancer Gene Ther 2004; 11: 397-407. (Pubitemid 38747371)
16. Kim J, Kim JH, Choi KJ, Kim PH, Yun CO. E1A-and E1B-double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Hum Gene Ther 2007; 18: 773-786. (Pubitemid 47502844)
17. Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798-806. (Pubitemid 30159332)
18. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61: 7464-7472. (Pubitemid 32995035)
19. Freytag SO, Khil M, Stricker H, Peabody J, Menon M, DePeralta-Venturina M et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002; 62: 4968-4976. (Pubitemid 34984421)
20. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271: 58-65.
21. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133: 95-109.
22. Martin-Fontecha A, Baumjohann D, Guarda G, Reboldi A, Hons M, Lanzavecchia A et al. CD40L+ CD4+ memory T cells migrate in a CD62P-dependent fashion into reactive lymph nodes and license dendritic cells for T cell priming. J Exp Med 2008; 205: 2561-2574.
23. Stemberger C, Huster KM, Koffler M, Anderl F, Schiemann M, Wagner H et al. A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets. Immunity 2007; 27: 985-997. (Pubitemid 50014865)
24. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004; 202: 275-293. (Pubitemid 39576919)
25. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 2004; 58: 24-38. (Pubitemid 38117046)
26. Carrio R, Lopez DM. Impaired thymopoiesis occurring during the thymic involution of tumor-bearing mice is associated with a down-regulation of the antiapoptotic proteins Bcl-XL and A1. Int J Mol Med 2009; 23: 89-98.
27. Fu Y, Paul RD, Wang Y, Lopez DM. Thymic involution and thymocyte phenotypic alterations induced by murine mammary adenocarcinomas. J Immunol 1989; 143: 4300-4307. (Pubitemid 20012631)
28. Ohm JE, Gabrilovich DI, Sempowski GD, Kisseleva E, Parman KS, Nadaf S et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003; 101: 4878-4886. (Pubitemid 36857749)
29. Yoo JY, Kim JH, Kwon YG, Kim EC, Kim NK, Choi HJ et al. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther 2007; 15: 295-302. (Pubitemid 46111879)
30. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009; 69: 609-615.
31. Hill HC, Conway Jr TF, Sabel MS, Jong YS, Mathiowitz E, Bankert RB et al. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 2002; 62: 7254-7263. (Pubitemid 36025247)
32. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146. (Pubitemid 37328691)
33. Helguera G, Rodriguez JA, Daniels TR, Penichet ML. Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies. Cancer Immunol Immunother 2007; 56: 1507-1512. (Pubitemid 47024716)
34. Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol 2007; 25: 171-192. (Pubitemid 46697906)
35. Zhang M. The relationships between thymus, other immune organs and various diseases in children (analysis of 621 cases)]. Zhonghua Bing Li Xue Za Zhi 1989; 18: 92-95.
36. Lopez DM, Charyulu V, Adkins B. Influence of breast cancer on thymic function in mice. J Mammary Gland Biol Neoplasia 2002; 7: 191-199. (Pubitemid 38420775)
37. Li L, Hsu HC, Stockard CR, Yang P, Zhou J, Wu Q et al. IL-12 inhibits thymic involution by enhancing IL-7-and IL-2-induced thymocyte proliferation. J Immunol 2004; 172: 2909-2916. (Pubitemid 38263677)
38. Stewart-Akers AM, Cairns JS, Tweardy DJ, McCarthy SA. Granulocyte-macrophage colony-stimulating factor augmentation of T-cell receptor-dependent and T-cell receptor-independent thymocyte proliferation. Blood 1994; 83: 713-723. (Pubitemid 24043732)
39. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-1103. (Pubitemid 26338628)
40. Dias S, Boyd R, Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer 1998; 78: 361-365. (Pubitemid 28445375)
41. Yun CO, Kim E, Koo T, Kim H, Lee YS, Kim JH. ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis. Cancer Gene Ther 2005; 12: 61-71. (Pubitemid 39665244)
42. Yoo JY, Kim JH, Kim J, Huang JH, Zhang SN, Kang YA et al. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibitiondelim. Gene Therapy 2008; 15: 635-651. (Pubitemid 351524518)